Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig in Moderate-to-Severe Atopic Dermatitis (Phase 2b)
2024-511549-20-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of lunsekimig in atopic dermatitis (AD) (4 arms), sponsored by Sanofi. Primary endpoint: Percent change in Eczema Area and Severity Index (EASI) score from baseline to Week 24. Started Apr 2025; status: completed.
02
Drugs
lunsekimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-511549-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511549-20-00.